Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Alexander Schmitz, Karen Dybkær, Hans Erik Johnsen et al.|BMC Cancer|2022

Cited by 7